C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER)

Sattar, N. et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation, 115(8), pp. 981-989. (doi:10.1161/CIRCULATIONAHA.106.643114)

Full text not currently available from Enlighten.

Abstract

<p><b><i>Background</i></b> - The role of C-reactive protein (CRP) in predicting vascular events and response to statin therapy remains uncertain. Additional large prospective studies are required.</p> <p><b><i>Methods and Results</i></b> - Baseline CRP was related to risk over 3.2 years for primary a combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke; n = 865 events) and secondary (coronary heart disease events or stroke alone) and tertiary (stroke plus transient ischemic attack) end points in the Prospective Study of Pravastatin in the Elderly at Risk (n = 5804 men and women; age, 70 to 82 years). CRP levels were higher in subjects who had a subsequent primary end-point event compared with those who did not (geometric mean; 3.64 mg/L [SD, 3.08 mg/L] versus 3.01 mg/L [SD, 3.05 mg/L]; P < 0.0001). CRP correlated positively with body mass index and smoking status and negatively with high-density lipoprotein cholesterol. The unadjusted hazard ratio for the primary end point was 1.48 (95% CI, 1.26 to 1.74) in a comparison of top and bottom thirds for CRP, falling to 1.36 (95% CI, 1.15 to 1.61) with adjustment for established predictors and body mass index. Similar results were obtained for other end points or when results were examined separately by history of vascular disease. However, baseline CRP added minimally to risk prediction beyond conventional predictors and did not relate to the magnitude of pravastatin benefit.</p> <p><b><i>Conclusions</i></b> - Elevated CRP minimally enhances cardiovascular disease prediction beyond established vascular risk factors and does not predict response to statin therapy in elderly subjects at risk. These data suggest that CRP has limited clinical value in cardiovascular disease risk stratification or predicting response to statin therapy in elderly people.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Macfarlane, Professor Peter and McConnachie, Professor Alex and Stott J, Professor David and Ford, Professor Ian and Shepherd, Prof James and Gaw, Dr Allan and Packard, Professor Chris and Cobbe, Professor Stuart and Murray, Mrs Heather and Sattar, Professor Naveed
Authors: Sattar, N., Murray, H., McConnachie, A., Blauw, G.J., Bollen, E.L.E.M., Buckley, B.M., Cobbe, S.M., Ford, I., Gaw, A., Hyland, M., Jukema, J.W., Kamper, A.M., Macfarlane, P.W., Murphy, M.B., Packard, C.J., Perry, I.J., Stott, D., Sweeney, B.J., Twomey, C., Westendorp, R.G.J., and Shepherd, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
?? 20206000 ??
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Circulation
Publisher:Lippincott Williams & Wilkins
ISSN:0009-7322
ISSN (Online):1524-4539
Published Online:05 February 2007

University Staff: Request a correction | Enlighten Editors: Update this record